SCHEMBL424061

SCHEMBL424061

Cc1cc(O)cc2c1NC(=O)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.42
CYP11B1 P15538 4/20 0.38
CYP11B2 P19099 4/20 0.38
CYP19A1 P11511 3/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CHRM1 P11229 1/20 0.38
ALOX15 P16050 1/20 0.38
MAOA P21397 1/20 0.38
TBXA2R P21731 1/20 0.38
ADRA1A P35348 1/20 0.38
HTR2B P41595 1/20 0.38
BRD4 O60885 10/20 0.36
BRD2 P25440 1/20 0.36
BRD3 Q15059 1/20 0.36
BRDT Q58F21 1/20 0.36
NPC1 O15118 1/20 0.35
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18208031 0.84 GRIA1 (0.43) AKT1CYP3A4CHRM1ALOX15MAOA
SCHEMBL434019 0.81 KMT2A (0.40) CYP11B1CYP11B2CYP19A1CYP1A2BRD4
SCHEMBL428384 0.80 CYP11B1 (0.51) CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4
SCHEMBL18513259 0.79 CYP11B1 (0.43) CYP11B1CYP11B2CYP19A1CYP1A2ALOX15
SCHEMBL7268522 0.79 CA9 (0.46) CYP11B1CYP11B2CYP19A1CYP1A2BRD4
SCHEMBL1289709 0.79 KIF11 (0.46) CYP11B1CYP11B2CYP19A1CYP1A2NPC1
SCHEMBL30946995 0.78 CYP11B1 (0.36) CYP11B1CYP11B2CYP19A1CYP1A2BRD4
SCHEMBL15828563 0.77 KIF11 (0.42) CYP11B1CYP11B2CYP19A1CYP1A2BRD4
SCHEMBL13052361 0.76 KIF11 (0.41) CYP11B1CYP11B2CYP19A1CYP1A2HTR2B
SCHEMBL25648918 0.76 PKM (0.41) CYP11B1CYP11B2CYP19A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109988093-B Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine 广东东阳光药业有限公司 2023-04-07 CN disclosed
US-8609847-B2 Dihydroquinolinone derivatives TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-12-17 US disclosed
EP-2393802-B1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO LTD (JP) 2013-05-08 EP disclosed
US-20120022064-A1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-26 US disclosed
US-20120022064-A1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-26 US disclosed
EP-2393802-A1 DIHYDROQUINOLINONE DERIVATIVES Taisho Pharmaceutical Co., Ltd. (JP) 2011-12-14 EP disclosed
WO-2010090347-A1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-08-12 WO disclosed
WO-2010090347-A1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022064-A1 DIHYDROQUINOLINONE DERIVATIVES PER2, CRY1, BACE1 AKT1 2554/4885CYP11B1 918/4885CYP11B2 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.